JENNIFER HART: Open Payments
NPI 1780815985 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,548 in 58 payments from 19 companies in 2025. Trend: 2023 $1,128 · 2024 $1,245 · 2025 $1,548
Food & beverage: $1,548
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $452 |
| Neurocrine BioSciences, Inc. | 1 | $125 |
| Ardelyx, Inc. | 1 | $125 |
| Sage Therapeutics, LLC | 1 | $120 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $115 |
| AstraZeneca Pharmaceuticals LP | 4 | $96 |
| Inspire Medical Systems, Inc. | 2 | $87 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $67 |
| Novo Nordisk Inc | 3 | $61 |
| Lilly USA, LLC | 2 | $49 |
Products named: VRAYLAR, QULIPTA, IBSRELA, Kerendia, AIRSUPRA, INSPIRE, CAPLYTA, UBRELVY.
Industry payments across LA — which companies pay providers there.
